Veracyte (VCYT) Liabilities and Shareholders Equity (2012 - 2026)

Veracyte has disclosed Liabilities and Shareholders Equity across 15 years of filings, most recently posting $1.4 billion for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $1.4 billion, up 9.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.6 billion (up 8.38% YoY), and the FY2025 annual result was $1.4 billion, up 8.15% from the prior year.
• Liabilities and Shareholders Equity came in at $1.4 billion for Q1 2026 at Veracyte, up from $1.4 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.4 billion in Q1 2026 to a low of $1.1 billion in Q4 2023.
• The 5-year median for Liabilities and Shareholders Equity is $1.2 billion (2024), against an average of $1.2 billion.
• Across the five-year window, Liabilities and Shareholders Equity fell 5.09% in 2022 and rose 16.6% in 2024, its largest moves.
• Veracyte's Liabilities and Shareholders Equity stood at $1.2 billion in 2022, then fell by 3.59% to $1.1 billion in 2023, then grew by 16.6% to $1.3 billion in 2024, then rose by 8.15% to $1.4 billion in 2025, then gained by 2.16% to $1.4 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.4 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.